标签归档：human

RFRP-1(human)

发表于由
回复

RFRP-1(human); 纯度: 99.32%

RFRP-1(human) 是促性腺激素抑制激素 (GnIH) 的同系物。RFRP-1(human) 靶向人类促性腺激素释放激素 (GnRH) 神经元和促性腺激素，并有效抑制促性腺激素。RFRP-1(human) 是一种有效的神经肽 FF (NPFF) 受体激动剂，对 NPFF2 和 NPFF1 的 EC50 分别为 0.0011 nM 和 29 nM。

RFRP-1(human)amp;;

RFRP-1(human) Chemical Structure

CAS No. : 311309-25-8

规格 价格 是否有货 数量
5 mg ￥3100 In-stock
10 mg ￥5500 In-stock
50 mg ; 询价 ;
100 mg ; 询价 ;

* Please select Quantity before adding items.

RFRP-1(human) 相关产品

bull;相关化合物库:

  • Bioactive Compound Library Plus
  • GPCR/G Protein Compound Library
  • Neuronal Signaling Compound Library
  • Endocrinology Compound Library
  • Neurotransmitter Receptor Compound Library
  • Anti-Obesity Compound Library
  • Targeted Diversity Library
  • Peptide Library

生物活性

RFRP-1(human) is a gonadotropin-inhibitory hormone (GnIH) homolog. RFRP-1(human) targets human gonadotropin-releasing hormone (GnRH) neurons and gonadotropes and potently inhibits gonadotropin. RFRP-1(human) is a potent Neuropeptide FF (NPFF) receptor agonist with EC50s of 0.0011 nM and 29 nM for NPFF2 and NPFF1, respectively[1][2][3].

体内研究
(In Vivo)

RFRP-1(human) rapidly and reversibly decreases shortening and relaxation in isolated mammalian cardiac myocytes in a dose dependent manner[2].
Intravenous injection of RFRP-1(human) in mice decreases heart rate, stroke volume, ejection fraction, and cardiac output[2].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.
分子量

1428.72

Formula

C67H101N19O14S
CAS 号

311309-25-8
Sequence Shortening

MPHSFANLPLRF-NH2
运输条件

Room temperature in continental US; may vary elsewhere.
储存方式

Sealed storage, away from moisture

Powder -80deg;C 2 years
-20deg;C 1 year

*In solvent : -80deg;C, 6 months; -20deg;C, 1 month (sealed storage, away from moisture)
溶解性数据
In Vitro:;

H2O : 100 mg/mL (69.99 mM; Need ultrasonic)

配制储备液
浓度 溶剂体积 质量 1 mg 5 mg 10 mg
1 mM 0.6999 mL 3.4996 mL 6.9993 mL
5 mM 0.1400 mL 0.6999 mL 1.3999 mL
10 mM 0.0700 mL 0.3500 mL 0.6999 mL

*

请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。
储备液的保存方式和期限：-80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)。-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。
参考文献

  • [1]. Takayoshi Ubuka, et al. Identification of human GnIH homologs, RFRP-1 and RFRP-3, and the cognate receptor, GPR147 in the human hypothalamic pituitary axis. PLoS One. 2009 Dec 22;4(12):e8400.

    [2]. R Nichols, et al. Human RFamide-related peptide-1 diminishes cellular and integrated cardiac contractile performance. Peptides. 2010 Nov;31(11):2067-74.

    [3]. C Gouardères, et al. Functional differences between NPFF1 and NPFF2 receptor coupling: high intrinsic activities of RFamide-related peptides on stimulation of [35S]GTPgammaS binding. Neuropharmacology. 2007 Feb;52(2):376-86.

M2e, human TFA

发表于由

M2e, human TFA; 纯度: 99.37%

M2e, human TFA 由 23 个 M2 (流感病毒A的第三个完整膜蛋白) 胞外残基组成，在所有人流感病毒 A 株中都有显著的保守性。M2e, human TFA 是一种有效且多用途的疫苗候选，可预防人类流感病毒 A 株。

M2e, human TFAamp;;

M2e, human TFA Chemical Structure

规格 价格 是否有货 数量
5 mg ￥3800 In-stock
10 mg ￥6000 In-stock
50 mg ; 询价 ;
100 mg ; 询价 ;

* Please select Quantity before adding items.

M2e, human TFA 相关产品

bull;相关化合物库:

  • Bioactive Compound Library Plus
  • Peptide Library

生物活性

M2e, human TFA, consisting of the 23 extracellular residues of M2 (the third integral membrane protein of influenza A), has been remarkably conserved in all human influenza A. M2e, human TFA is a valid and versatile vaccine candidate to protect against any strain of human influenza A[1].

分子量

2738.83

Formula

C109H171F3N32O43S2
Sequence

Ser-Leu-Leu-Thr-Glu-Val-Glu-Thr-Pro-Ile-Arg-Asn-Glu-Trp-Gly-Cys-Arg-Cys-Asn-Asp-Ser-Ser-Asp
Sequence Shortening

SLLTEVETPIRNEWGCRCNDSSD
运输条件

Room temperature in continental US; may vary elsewhere.
储存方式

Sealed storage, away from moisture

Powder -80deg;C 2 years
-20deg;C 1 year

*In solvent : -80deg;C, 6 months; -20deg;C, 1 month (sealed storage, away from moisture)
溶解性数据
In Vitro:;

DMSO : 100 mg/mL (36.51 mM; Need ultrasonic)

配制储备液
浓度 溶剂体积 质量 1 mg 5 mg 10 mg
1 mM 0.3651 mL 1.8256 mL 3.6512 mL
5 mM 0.0730 mL 0.3651 mL 0.7302 mL
10 mM 0.0365 mL 0.1826 mL 0.3651 mL

*

请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。
储备液的保存方式和期限：-80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)。-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。
参考文献

  • [1]. De Filette M, et al. Improved design and intranasal delivery of an M2e-based human influenza A vaccine. Vaccine. 2006 Nov 10;24(44-46):6597-601.

Human PD-L1 inhibitor V TFA

发表于由

Human PD-L1 inhibitor V TFA; 纯度: 96.63%

Human PD-L1 inhibitor V TFA 是一种 human PD-1 protein 结合肽，Kd 值为 3.32 μM，可抑制人 PD-1/PD-L1 的结合。

Human PD-L1 inhibitor V TFAamp;;

Human PD-L1 inhibitor V TFA Chemical Structure

规格 价格 是否有货 数量
10 mg ￥2900 In-stock
50 mg ; 询价 ;
100 mg ; 询价 ;

* Please select Quantity before adding items.

Human PD-L1 inhibitor V TFA 相关产品

bull;相关化合物库:

  • Bioactive Compound Library Plus
  • Immunology/Inflammation Compound Library
  • Small Molecule Immuno-Oncology Compound Library
  • Anti-Breast Cancer Compound Library
  • Anti-Lung Cancer Compound Library
  • Anti-Blood Cancer Compound Library
  • Anti-Liver Cancer Compound Library
  • Anti-Colorectal Cancer Compound Library
  • Peptide Library

生物活性

Human PD-L1 inhibitor V TFA, a human PD-1 protein binding peptide with a Kd value of 3.32 μM. Human PD-L1 inhibitor V TFA inhibit the interaction of hPD-1/hPD-L1[1].

体外研究
(In Vitro)

Human PD-L1 inhibitor V (Ar5M_2) is a peptide designed with anchor residues Y56, R113, A121, D122 and Y123[1].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.
分子量

1599.73

Formula

C67H1045F3N20O20S
Sequence Shortening

LDYVNRRKMYQ
运输条件

Room temperature in continental US; may vary elsewhere.
储存方式

Sealed storage, away from moisture

Powder -80deg;C 2 years
-20deg;C 1 year

*In solvent : -80deg;C, 6 months; -20deg;C, 1 month (sealed storage, away from moisture)
溶解性数据
In Vitro:;

H2O : 100 mg/mL (62.51 mM; Need ultrasonic)

配制储备液
浓度 溶剂体积 质量 1 mg 5 mg 10 mg
1 mM 0.6251 mL 3.1255 mL 6.2511 mL
5 mM 0.1250 mL 0.6251 mL 1.2502 mL
10 mM 0.0625 mL 0.3126 mL 0.6251 mL

*

请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。
储备液的保存方式和期限：-80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)。-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。
参考文献

  • [1]. Qiao Li, et al. Discovery of peptide inhibitors targeting human programmed death 1 (PD-1) receptor. Oncotarget. 2016 Oct 4;7(40):64967-64976.

Kisspeptin-10, human(Synonyms: 亲吻促动素-10(人源))

发表于由

Kisspeptin-10, human;(Synonyms: 亲吻促动素-10(人源))

Kisspeptin-10, human 是一种有效的血管收缩剂和血管生成抑制剂。Kisspeptin-10, human 通过其受体 GPR54 来抑制肿瘤转移作用。Kisspeptin-10-GPR54 系统在胚胎肾脏发育中起重要作用。Kisspeptin-10/GPR54 信号通过 NFATc4 介导的 BMP2 表达来诱导成骨细胞分化。

Kisspeptin-10, humanamp;;(Synonyms: 亲吻促动素-10(人源))

Kisspeptin-10, human Chemical Structure

CAS No. : 374675-21-5

规格 是否有货
100 mg ; 询价 ;
250 mg ; 询价 ;
500 mg ; 询价 ;

* Please select Quantity before adding items.

Kisspeptin-10, human 的其他形式现货产品:

Kisspeptin-10, human TFA

生物活性

Kisspeptin-10, human is a potent vasoconstrictor and inhibitor of angiogenesis. Kisspeptin-10, human acts as a tumor metastasis suppressor via its receptor GPR54. Kisspeptin-10-GPR54 system plays an important role in embryonic kidney development. Kisspeptin-10/GPR54 signaling induces osteoblast differentiation via NFATc4-mediated BMP2 expression[1].

IC50 Target

GPR54[1]
Angiogenesis[1]
体外研究
(In Vitro)

Kisspeptin-10 (KP-10) and its receptor GPR54 are key components in the regulation of GnRH secretion in humans and other mammals. Kisspeptin-10 protein binds to GPR54. Activation of Kisspeptin-10 suppresses pulmonary human melanoma and Kisspeptin-10 is a metastasis suppressor in breast cancer cells[1].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.
分子量

1302.44

Formula

C63H83N17O14
CAS 号

374675-21-5
Sequence

Tyr-Asn-Trp-Asn-Ser-Phe-Gly-Leu-Arg-Phe-NH2
Sequence Shortening

YNWNSFGLRF-NH2
中文名称

亲吻促动素-10(人源)
运输条件

Room temperature in continental US; may vary elsewhere.
储存方式

Please store the product under the recommended conditions in the Certificate of Analysis.
Solvent Solubility
In Vitro:;

H2O

Peptide Solubility and Storage Guidelines:

1.;;Calculate the length of the peptide.

2.;;Calculate the overall charge of the entire peptide according to the following table:

; Contents Assign value
Acidic amino acid Asp (D), Glu (E), and the C-terminal -COOH. -1
Basic amino acid Arg (R), Lys (K), His (H), and the N-terminal -NH2 +1
Neutral amino acid Gly (G), Ala (A), Leu (L), Ile (I), Val (V), Cys (C), Met (M), Thr (T), Ser (S), Phe (F), Tyr (Y), Trp (W), Pro (P), Asn (N), Gln (Q) 0

3.;;Recommended solution:

Overall charge of peptide Details
Negative (lt;0) 1.;;Try to dissolve the peptide in water first.
2.;;If water fails, add NH4OH (lt;50 μL).
3.;;If the peptide still does not dissolve, add DMSO (50-100 μL) to solubilize the peptide.
Positive (gt;0) 1.;;Try to dissolve the peptide in water first.
2.;;If water fails, try dissolving the peptide in a 10%-30% acetic acid solution.
3.;;If the peptide still does not dissolve, try dissolving the peptide in a small amount of DMSO.
Zero (=0) 1.;;Try to dissolve the peptide in organic solvent (acetonitrile, methanol, etc.) first.
2.;;For very hydrophobic peptides, try dissolving the peptide in a small amount of DMSO, and then dilute the solution with water to the desired concentration.
参考文献

  • [1]. Son HE, et al. Kisspeptin-10 (KP-10) stimulates osteoblast differentiation through GPR54-mediated regulation of BMP2 expression and activation. Sci Rep. 2018 Feb 1;8(1):2134.

ELA-32(human) TFA

发表于由

ELA-32(human) TFA; 纯度: 99.27%

ELA-32(human) TFA is a potent, high affinity apelin receptor agonist (IC50=0.27 nM; Kd=0.51 nM). ELA-32(human) TFA exhibits no binding GPR15 and GPR25. ELA-32(human) TFA activates the PI3K/AKT pathway and promotes self-renewal of hESCs via cell-cycle progression and protein translation. ELA-32(human) TFA also potentiates the TGFβ pathway, priming hESCs toward the endoderm lineage. ELA-32(human) TFA stimulates angiogenesis in HUVEC cells.

ELA-32(human) TFAamp;;

ELA-32(human) TFA Chemical Structure

规格 价格 是否有货 数量
5 mg ￥6500 In-stock
10 mg ￥9800 In-stock
50 mg ; 询价 ;
100 mg ; 询价 ;

* Please select Quantity before adding items.

生物活性

ELA-32(human) TFA is a potent, high affinity apelin receptor agonist (IC50=0.27 nM; Kd=0.51 nM). ELA-32(human) TFA exhibits no binding GPR15 and GPR25. ELA-32(human) TFA activates the PI3K/AKT pathway and promotes self-renewal of hESCs via cell-cycle progression and protein translation. ELA-32(human) TFA also potentiates the TGFβ pathway, priming hESCs toward the endoderm lineage. ELA-32(human) TFA stimulates angiogenesis in HUVEC cells.

分子量

4081.84

Formula

C172H290F3N63O41S4
Sequence Shortening

QRPVNLTMRRKLRKHNCLQRRCMPLHSRVPFP (Disulfide bridge: Cys17-Cys22)
运输条件

Room temperature in continental US; may vary elsewhere.
储存方式

Protect from light, stored under nitrogen

Powder -80deg;C 2 years
-20deg;C 1 year

*In solvent : -80deg;C, 6 months; -20deg;C, 1 month (protect from light, stored under nitrogen)
溶解性数据
In Vitro:;

H2O : 100 mg/mL (24.50 mM; Need ultrasonic)

配制储备液
浓度 溶剂体积 质量 1 mg 5 mg 10 mg
1 mM 0.2450 mL 1.2249 mL 2.4499 mL
5 mM 0.0490 mL 0.2450 mL 0.4900 mL
10 mM 0.0245 mL 0.1225 mL 0.2450 mL

*

请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。
储备液的保存方式和期限：-80°C, 6 months; -20°C, 1 month (protect from light, stored under nitrogen)。-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。

Neuronostatin-13 (human)

发表于由

Neuronostatin-13 (human);

Neuronostatin-13 human 是一种由生长抑素基因编码的由 13 个氨基酸组成的肽激素，在调节激素和心脏功能中起着重要作用。

Neuronostatin-13 (human)amp;;

Neuronostatin-13 (human) Chemical Structure

CAS No. : 1096485-24-3

规格 价格 是否有货
1 mg ￥2200 询问价格 货期
5 mg ￥6600 询问价格 货期

* Please select Quantity before adding items.

生物活性

Neuronostatin-13 human is a 13-amino acid peptide hormone encoded by the somatostatin gene and plays an important role in the regulation of hormonal and cardiac function.

体外研究
(In Vitro)

Neuronostatin-13 human is a 13-amino acid peptide hormone encoded by the somatostatin gene and plays an important role in the regulation of hormonal and cardiac function. Treatment with Neuronostatin-13 human (1,000 nM) enhances low-glucose-induced glucagon release compare with islets treated with control medium alone. Treatment with Neuronostatin-13 human for 1 h leads to a significant increase in the accumulation of glucagon mRNA compare with vehicle-treated control cells. In αTC1-9 α-cells, treatment with 100 nM Neuronostatin-13 human leads to an increase in phosphorylated PKA at 30 and 40 min[1].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.
体内研究
(In Vivo)

Infusion with Neuronostatin-13 human delays glucose clearance in the rat model, such that blood glucose levels in Neuronostatin-13 human-treated animals are significantly higher at 1 and 10 min following intra-arterial injection of a glucose bolus[1]. Chocardiographic measurement reveals a remarkable drop in heart rate after 3-, 6- and 12-hr of Neuronostatin-13 human challenge. In addition, Neuronostatin-13 human treatment significantly decreases left ventricular end-systolic diameter (LVESD) and fractional shortening without affecting left ventricular end-diastolic diameter (LVEDD) between 6 and 12 hrs following Neuronostatin-13 human challenge, the effect of which returns to basal level 18-hr after Neuronostatin-13 human treatment[2].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.
分子量

1415.68

Formula

C64H110N20O16
CAS 号

1096485-24-3
Sequence Shortening

LRQFLQKSLAAAA-NH2
运输条件

Room temperature in continental US; may vary elsewhere.
储存方式
Powder -80deg;C 2 years
-20deg;C 1 year
In solvent -80deg;C 6 months
-20deg;C 1 month
Solvent Solubility
In Vitro:;

H2O

Peptide Solubility and Storage Guidelines:

1.;;Calculate the length of the peptide.

2.;;Calculate the overall charge of the entire peptide according to the following table:

; Contents Assign value
Acidic amino acid Asp (D), Glu (E), and the C-terminal -COOH. -1
Basic amino acid Arg (R), Lys (K), His (H), and the N-terminal -NH2 +1
Neutral amino acid Gly (G), Ala (A), Leu (L), Ile (I), Val (V), Cys (C), Met (M), Thr (T), Ser (S), Phe (F), Tyr (Y), Trp (W), Pro (P), Asn (N), Gln (Q) 0

3.;;Recommended solution:

Overall charge of peptide Details
Negative (lt;0) 1.;;Try to dissolve the peptide in water first.
2.;;If water fails, add NH4OH (lt;50 μL).
3.;;If the peptide still does not dissolve, add DMSO (50-100 μL) to solubilize the peptide.
Positive (gt;0) 1.;;Try to dissolve the peptide in water first.
2.;;If water fails, try dissolving the peptide in a 10%-30% acetic acid solution.
3.;;If the peptide still does not dissolve, try dissolving the peptide in a small amount of DMSO.
Zero (=0) 1.;;Try to dissolve the peptide in organic solvent (acetonitrile, methanol, etc.) first.
2.;;For very hydrophobic peptides, try dissolving the peptide in a small amount of DMSO, and then dilute the solution with water to the desired concentration.
参考文献

  • [1]. Salvatori AS, et al. Neuronostatin inhibits glucose-stimulated insulin secretion via direct action on the pancreatic α-cell. Am J Physiol Endocrinol Metab. 2014 Jun 1;306(11):E1257-63.

    [2]. Zhu X, et al. Neuronostatin attenuates myocardial contractile function through inhibition of sarcoplasmic reticulum Ca2+-ATPase in murine heart. Cell Physiol Biochem. 2014;33(6):1921-32.
Cell Assay
[1]

For studies examining hormone secretion from cell lines, INS 832/13 or αTC1-9 cells are plated in 96- or 24-well plates at a density of 0.25×105 cells/well or 1.0×105 cells/well in complete medium. The day of the experiment, cells are washed in PBS and allowed to preincubate in low- or high-glucose KRB buffer for 1 h in the presence or absence of Neuronostatin-13 human. Hormone secretion is performed using a 2-h static incubation. Supernatants are collected, and insulin or glucagon content is determined[1].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.
Animal Administration
[2]

3-month-old adult male C57BL/6 mice are used and housed in a temperature-controlled environment (22.8±2.0°C, 45 to 50% humidity) with a 12:12h light/dark cycle with free access to food and tap water. For Neuronostatin-13 human challenge in vivo, 3-month-old adult C57BL/6 male mice are randomly divided into two groups and to receive Neuronostatin-13 human (50 μg/kg, i.p.). Cardiac function is evaluated at 3-, 6-, 12- and 18-hr after Neuronostatin-13 human treatment in the first group of animals[2].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.
参考文献

  • [1]. Salvatori AS, et al. Neuronostatin inhibits glucose-stimulated insulin secretion via direct action on the pancreatic α-cell. Am J Physiol Endocrinol Metab. 2014 Jun 1;306(11):E1257-63.

    [2]. Zhu X, et al. Neuronostatin attenuates myocardial contractile function through inhibition of sarcoplasmic reticulum Ca2+-ATPase in murine heart. Cell Physiol Biochem. 2014;33(6):1921-32.

Human Domain Antibody Library (DAb library)

发表于由

Human Domain Antibody Library源自MRC Daniel Christ实验室， Human Domain Antibody Library明显优于Tomlinson I + J 文库，可以通过噬菌体展示技术产生针对任何目的抗原的抗体。该类抗体可用于ELISA, Western blotting, FACS, IHC等免疫学试验。该噬菌体文库已经在很多分子生物学实验室成功使用，可在大量不同的蛋白，多肽，小分子复合物中诱导出特异性抗体反应物。

噬菌体展示技术利用基因克隆技术将B细胞全套可变区基因克隆出来，组装到表达载体内并表达到噬菌体表面，并通过“吸附-洗脱-扩增”的富集过程，从中筛选特异性抗体的可变区基因。Human Domain Antibody构建在pR2(MYC VSV  标签)上，多元化的侧链在 CDR1、CDR2 和 CDR 3：H27 33、H35、H50、H52 H54、H94、H95-H100(a-k)、H101、H102。经过筛选后与突变的多样性体细胞共同作用使其成熟。该文库基于VH框架（V3-23/D47），抗原结合区域的多样性的引入通过PCR突变CDR1、CDR2和CDR3。此文库有以下优点：

· 产生结合剂到模型折叠抗原上，无冷却后抗原结合活性的重大损失。

· 抗体选择后，通过25次热变形循环，竞争抗耐性的嗜热蛋白如Taq酶，保持抗原结合活性。

· 在噬菌体中，所有组分可经受热诱导聚集反应。

以上提到的优点，可为诊断和治疗的研究与应用提供广泛领域，可以进一步实现较大化结合你感兴趣的抗原数量。

文库以下面形式提供：

· Phagemid antibody library (~3×10 9 )

· Helper phage KM13

· Host strain TG1Tr

· Optimised antibody expression strain HB2151

· Controls: anti-beta-galactosidase & anti-bovine ubiquitin antibodies

· Detailed protocol

Source Bioscience (Geneservice)与全球多个科研机构（如NIH、NKI、Sanger等）建立合作关系，拥有全球较大的cDNA、基因组、噬菌体展示、microRNA、siRNA、shRNA与MGC收藏库，涉及物种包括人、小鼠、大鼠、牛，以及各种模式动物如线虫、斑马鱼、果蝇、原鸡、爪蟾等，产品达1600多万种。Human Domain Antibody Library是Source Bioscience提供的较为成熟的一个文库，除此之外，还有Tomlinson I + J 文库，以及ATLAS scFV library。

更多产品可点击 Source Bioscience查询具体信息。

上海金畔生物科技有限公司成为美国Source Bioscience中国地区一级代理，双方携手为国内科研工作者提供物种齐全的克隆及文库，欢迎您来电咨询和申请。

The World’s Largest Commercial Clone Library

发表于由

The World’s Largest Commercial Clone Library

• Over 20 million clones
•  Sequence verification availab
•  Plasmid preparation service
•  Rapid turnaround times

CLONE PORTFOLIO
• cDNA/ORF (IMAGE, MGC, FANTOM
EST, ORF)
• RNAi (Human miRNA, shRNAm,
MISSION siRNA, C. elegans RNAi)
• Antibody libraries (Human Single
fold scFv libraries I + J, Human Domain
antibody library (DAb), ATLAS ScFV)
• Synthetic genes (made to order)

Genomic
•     Human (CpG island, TilePath BAC,
minimal genomic clone set, BAC
(RPCI-11)
•     C.elegans (promoterome library,
fosmid library)
•     Chicken (BAC, CpG island)
•     Drosophilia cosmid
•     Fugu (BAC, cosmid)
•     Mouse (bMQ BAC, BAC (RPCI-23),
PAC, Cosmid (strain 129/ola)
•     Zebrafish BAC
•     Pig CpG Island

GenomeCube
Clone and antibody
search engine

Intuitive and fast
search of the largest
publically available
database of over 20
million clones and
150,000 antibodies

Find out more:
Tel:   +86 10 8859-7838
Fax:   +86 10 8859-5011
Email: info@jinpanbio.com
Web:   www.jinpanbio.com
BEIJING SEAJET SCIENTIFIC CO., LTD.
Beijing Headquarters
Flat.15 A-B, Block A.
20 Yuanda Rd. Haidian District
Beijing 100089
China

Endothelin 1 (swine, human) (TFA)

发表于由

Endothelin 1 (swine, human) (TFA); 纯度: 98.50%

Endothelin 1 (swine, human) (TFA) 是具有人和猪内皮素 1 序列的合成肽，是有效的内源性血管收缩剂。Endothelin 1 通过两种类型受体 ETA 和 ETB 发挥作用。

Endothelin 1 (swine, human) (TFA)amp;;

Endothelin 1 (swine, human) (TFA) Chemical Structure

规格 价格 是否有货 数量
500 μg ￥1350 In-stock
1 mg ￥2400 In-stock
5 mg ￥9600 In-stock
10 mg ; 询价 ;
50 mg ; 询价 ;

* Please select Quantity before adding items.

生物活性

Endothelin 1 (swine, human) (TFA) is a synthetic peptide with the sequence of human and swine Endothelin 1, which is a potent endogenous vasoconstrictor. Endothelin 1 acts through two types of receptors ETA and ETB[1].

分子量

2605.92

Formula

C111H160 F3N25O34S5
Sequence

Cys-Ser-Cys-Ser-Ser-Leu-Met-Asp-Lys-Glu-Cys-Val-Tyr-Phe-Cys-His-Leu-Asp-Ile-Ile-Trp (Disulfide bridge: Cys1-Cys15, Cys3-Cys11)
Sequence Shortening

CSCSSLMDKECVYFCHLDIIW (Disulfide bridge: Cys1-Cys15, Cys3-Cys11)
运输条件

Room temperature in continental US; may vary elsewhere.
储存方式

Protect from light, stored under nitrogen

Powder -80deg;C 2 years
-20deg;C 1 year

*In solvent : -80deg;C, 6 months; -20deg;C, 1 month (protect from light, stored under nitrogen)
参考文献

  • [1]. Kowalczyk A, et al. The role of endothelin-1 and endothelin receptor antagonists in inflammatory response and sepsis. Arch Immunol Ther Exp (Warsz). 2015;63(1):41-52.

Fibrinopeptide A, human TFA(Synonyms: Human fibrinopeptide A TFA)

发表于由

Fibrinopeptide A, human TFA;(Synonyms: Human fibrinopeptide A TFA) 纯度: 98.78%

Fibrinopeptide A, human TFA 是由凝血酶从纤维蛋白原切割后的一种含 16 个氨基酸残基的短肽，位于 Aα 链的 NH2-末端。

Fibrinopeptide A, human TFAamp;;(Synonyms: Human fibrinopeptide A TFA)

Fibrinopeptide A, human TFA Chemical Structure

CAS No. : 61533-47-9

规格 价格 是否有货 数量
1 mg ￥1400 In-stock
5 mg ￥4500 In-stock
10 mg ￥6500 In-stock
50 mg ; 询价 ;
100 mg ; 询价 ;

* Please select Quantity before adding items.

Fibrinopeptide A, human TFA 相关产品

bull;相关化合物库:

  • Bioactive Compound Library Plus
  • Peptide Library

生物活性

Fibrinopeptide A, human TFA is a 16-residue short polypeptide cleaved from fibrinogen by thrombin. Fibrinopeptide A, human locates at the NH2-termini of the Aα chain[1].

体外研究
(In Vitro)

The conversion of monomeric fibrinogen into polymeric fibrin is mediated by thrombin, which binds to the central region of fibrinogen and catalyzes cleavage of the 2 short peptides, the 16-residue fibrinopeptide A (FpA) and the 14-residue fibrinopeptide B (FpB), located at the NH2-termini of the Aα and Bβ chains, respectively[1].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.
体内研究
(In Vivo)

Fibrinopeptide A (FPA) is a small polypeptide cleaved from fibrinogen by thrombin, has a short half-life, and is considered a sensitive biochemical marker of thrombin activity, fibrin generation, and ongoing thrombosis[2].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.
分子量

1764.60

Formula

C63H97N19O26.2C2HF3O2
CAS 号

61533-47-9
Sequence

Ala-Asp-Ser-Gly-Glu-Gly-Asp-Phe-Leu-Ala-Glu-Gly-Gly-Gly-Val-Arg
Sequence Shortening

ADSGEGDFLAEGGGVR
运输条件

Room temperature in continental US; may vary elsewhere.
储存方式

Sealed storage, away from moisture

Powder -80deg;C 2 years
-20deg;C 1 year

*In solvent : -80deg;C, 6 months; -20deg;C, 1 month (sealed storage, away from moisture)
Solvent Solubility
In Vitro:;

H2O

Peptide Solubility and Storage Guidelines:

1.;;Calculate the length of the peptide.

2.;;Calculate the overall charge of the entire peptide according to the following table:

; Contents Assign value
Acidic amino acid Asp (D), Glu (E), and the C-terminal -COOH. -1
Basic amino acid Arg (R), Lys (K), His (H), and the N-terminal -NH2 +1
Neutral amino acid Gly (G), Ala (A), Leu (L), Ile (I), Val (V), Cys (C), Met (M), Thr (T), Ser (S), Phe (F), Tyr (Y), Trp (W), Pro (P), Asn (N), Gln (Q) 0

3.;;Recommended solution:

Overall charge of peptide Details
Negative (lt;0) 1.;;Try to dissolve the peptide in water first.
2.;;If water fails, add NH4OH (lt;50 μL).
3.;;If the peptide still does not dissolve, add DMSO (50-100 μL) to solubilize the peptide.
Positive (gt;0) 1.;;Try to dissolve the peptide in water first.
2.;;If water fails, try dissolving the peptide in a 10%-30% acetic acid solution.
3.;;If the peptide still does not dissolve, try dissolving the peptide in a small amount of DMSO.
Zero (=0) 1.;;Try to dissolve the peptide in organic solvent (acetonitrile, methanol, etc.) first.
2.;;For very hydrophobic peptides, try dissolving the peptide in a small amount of DMSO, and then dilute the solution with water to the desired concentration.
参考文献

  • [1]. Riedel T, et al. Fibrinopeptides A and B release in the process of surface fibrin formation. Blood. 2011 Feb 3;117(5):1700-6.

    [2]. Manolis AS, et al. Plasma level changes of fibrinopeptide A after uncomplicated coronary angioplasty. Clin Cardiol. 1993 Jul;16(7):548-52.